Biosenta Inc (ZRO) AI Stock Analysis

• Market Cap: C$2.76M
• Dividend Yield: N/A
• Average Volume (3M): 2.93K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.26
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: CA
• Employees: N/A
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Household & Personal Products
• EPS (TTM): N/A
• Shares Outstanding: 34,456,387
• 10 Day Avg. Volume: 5,790
• 30 Day Avg. Volume: 2,930
• PEG Ratio: 0.59
• Price to Book (P/B): -0.40
• Price to Sales (P/S): 3296.23
• P/FCF Ratio: -8.29
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: C$0.07 ▼(-10.00% Downside)
• Action: Reiterated Date: 03/05/26
• Date: Action: Reiterated 03/05/26

The score is primarily constrained by weak financial performance (shrinking tiny revenue base, persistent losses, negative equity, and ongoing cash burn). Technicals also remain bearish with the stock below major moving averages, while valuation is difficult to support due to negative earnings and no dividend data.

Positive Factors

Improving free cash flow burn

Free cash flow burn has improved versus 2024, indicating management has taken actions to reduce cash outflows. A sustained reduction in cash burn lengthens runway, lowers near-term refinancing pressure, and provides a structurally stronger footing for executing a turnaround over the next several months.

Quality of reported losses

Free cash flow tracking net income at roughly 1x suggests losses are largely cash-based rather than driven by distortive non-cash items. That improves the reliability of cash forecasts and makes financing needs more predictable, a durable advantage for planning operational recovery or restructuring.

Smaller net losses vs 2023

Net losses have narrowed relative to an unusually large 2023 loss, implying progress on cost control or one-time issue remediation. If sustained, this reduction in loss magnitude supports improving leverage on any future revenue gains and reduces cumulative deficit growth over a multi-quarter horizon.

Negative Factors

Tiny, shrinking revenue base

Revenue is extremely small and declined ~22% YoY, which undermines the company’s ability to achieve scale or cover fixed costs. A contracting top line is a structural headwind: without credible, durable revenue growth the business cannot sustainably absorb operating expenses or fund reinvestment.

Negative gross profit and persistent losses

Negative gross profit indicates the core product economics do not cover direct costs, a fundamental business-model flaw. Persistent operating losses mean margins are structurally unsustainable unless product pricing, cost structure, or the revenue mix are materially changed over the medium term.

Deeply negative equity / stressed balance sheet

Equity is deeply negative (~-10.6M) against a tiny asset base, reflecting accumulated deficits and a fragile capital structure. This materially limits financial flexibility, increases reliance on external funding or restructuring, and is a long-running solvency risk absent decisive recapitalization.

Biosenta Inc Business Overview & Revenue Model

Company Description

Biosenta Inc. develops, manufactures, and sells anti-microbial chemical compounds for household and industrial applications in Canada. It is involved in developing true, an anti-microbial, dual-action disinfectant that kills viruses, bacteria, mold, and germs on contact. The company also intends to manufacture and distribute Tri-Filler, an anti-microbial filler to perform filling and bulking functions. Biosenta Inc. was founded in 1986 and is based in Toronto, Canada.

How the Company Makes Money

Biosenta Inc makes money primarily through the sale of its antimicrobial products, which are marketed to a wide range of customers, including individual consumers, businesses, and institutions. The company's revenue model is based on direct sales as well as partnerships with distributors and retailers who help extend the reach of Biosenta's product offerings. Key revenue streams include product sales in retail locations, online marketplaces, and through direct corporate partnerships. The company's focus on environmentally friendly and effective antimicrobial solutions positions it to capitalize on growing consumer demand for safer and more sustainable cleaning products. Any significant partnerships or licensing agreements that enhance product distribution or innovation capabilities also contribute to Biosenta's earnings.

Biosenta Inc Financial Statement Overview

Summary

Very small and declining revenue (TTM ~940, ~-22% YoY), negative gross profit, and deeply loss-making operations. The balance sheet is highly stressed with deeply negative equity (~-10.6M) against a very small asset base (~92K) and ongoing cash burn (TTM FCF ~-449K), despite some improvement versus prior periods.

Income Statement

TTM (Trailing-Twelve-Months) revenue is very small (940) and down meaningfully year over year (about -22%), highlighting a shrinking top line. Profitability is severely weak: gross profit is negative and operating results remain deeply loss-making (EBIT and net income both strongly negative), indicating the business is not covering core costs. A positive offset is that net losses have been far smaller than 2023’s unusually large loss, but results are still materially negative with no clear path to near-term profitability shown in the provided data.

Balance Sheet

The balance sheet is highly stressed, with stockholders’ equity deeply negative in the latest periods (TTM equity around -10.6M) versus a very small asset base (about 92K TTM), which suggests accumulated deficits dominate the capital structure. Total debt is present (about 866K TTM) and has risen versus 2025 annual, adding financial pressure even though it is below 2024’s peak debt level. Overall, the negative equity position is the key weakness and makes the company financially fragile.

Cash Flow

Cash generation remains weak: TTM operating cash flow and free cash flow are both negative (roughly -447K to -449K), implying ongoing cash burn. A relative positive is that free cash flow burn improved versus 2024 annual levels, and cash flow tracks net income closely (free cash flow to net income near 1x), suggesting losses are not being heavily distorted by non-cash items. Still, persistent negative operating cash flow indicates continued reliance on external funding or balance-sheet actions to sustain operations.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Sep 2021
Income Statement
Total Revenue	1.21K	1.38K	1.04K	1.15K	168.10K
Gross Profit	-1.78K	835.00	427.00	728.00	99.11K
EBITDA	-1.39M	-1.09M	-6.24M	-1.24M	-2.03M
Net Income	-2.51M	-2.23M	-6.30M	-1.46M	-2.05M
Balance Sheet
Total Assets	110.33K	113.54K	107.59K	256.08K	263.66K
Cash, Cash Equivalents and Short-Term Investments	26.49K	8.53K	5.88K	27.26K	111.88K
Total Debt	694.59K	5.55M	5.62M	94.77K	152.43K
Total Liabilities	10.17M	7.99M	7.96M	3.18M	2.86M
Stockholders Equity	-10.06M	-7.88M	-7.86M	-2.92M	-2.59M
Cash Flow
Free Cash Flow	-481.24K	-779.35K	-566.35K	-504.43K	-672.29K
Operating Cash Flow	-455.38K	-779.35K	-550.79K	-504.43K	-672.29K
Investing Cash Flow	-25.86K	0.00	-15.56K	0.00	0.00
Financing Cash Flow	499.20K	781.99K	544.97K	419.81K	739.86K

Biosenta Inc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.08
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ZRO, the sentiment is Negative. The current price of 0.08 is above the 20-day moving average (MA) of 0.08, below the 50-day MA of 0.09, and below the 200-day MA of 0.12, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 31.32 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:ZRO.

Biosenta Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
PSYC	47 Neutral	C$4.33M	-1.22	-70.53%	―	-41.18%	17.65%
ZRO	42 Neutral	C$2.76M	-1.38	―	―	―	―
LFST	41 Neutral	C$1.52M	1.34	-129.49%	―	-98.28%	76.18%
URAI	39 Underperform	C$25.05M	-6.90	-179.43%	―	―	-391.89%

Biosenta Inc Corporate Events

Biosenta to Test Antimicrobial Nanoparticles in Alberta Residential Project

Biosenta Inc. has entered into a Field Test and Research Agreement with Livespace Homes to evaluate the real-world performance of its antimicrobial nanoparticle technology in a residential construction setting. This initiative aims to generate field data on performance and durability, supporting commercialization planning and broader market adoption, potentially impacting the residential construction industry by enhancing the safety and cleanliness of living spaces.